78 completed, 52 recruiting, 29 unknown, 21 active not recruiting. 209 Phase 3, 20 Phase 2.
Follow Irinotecan: new trials by email Literature Review of Irinotecan trials Research Report on Irinotecan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1/PD-L1 Inhibitor Combined With Platinum-Based Chemotherapy. FH-006, Paclitaxel, Docetaxel, Irinotecan - Locally Advanced, Recurrent or Metastatic ESCC Patients Who Have Failed Prior PD-1/PD-L1 Inhibitors Combined With Platinum-based Chemotherapy | Phase 3 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 480 | 2026-10-13 | 2026-10-27 |
| Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2) Petosemtamab, Cetuximab, Bevacizumab - Colorectal Cancer | Phase 3 | Recruiting | Genmab | 600 | 2026-10-07 | 2026-10-09 |
| Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma | Phase 3 | Recruiting | City of Hope Medical Center | 129 | 2026-10-01 | 2026-09-25 |
| Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients FOLFIRI+cetuximab, Guardant360 ctDNA assay - Colorectal Cancer Metastatic | Phase 3 | Not yet recruiting | Charite University, Berlin, Germany | 267 | 2026-10-01 | 2026-07-29 |
| A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma ATG-022, Docetaxel or Irinotecan - Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 3 | Recruiting | Antengene Biologics Limited | 380 | 2026-09-17 | 2026-10-29 |
| Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature Oxaliplatin, Irinotecan, Folinic acid - Pancreatic Ductal Adenocarcinoma | Phase 3 | Recruiting | John Neoptolemos | 394 | 2026-08-17 | 2026-08-27 |
| A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) HS-20093 for Injection, Irinotecan; Paclitaxel; Docetaxel - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 3 | Not yet recruiting | Hansoh BioMedical R&D Company | 494 | 2026-07-31 | 2026-06-02 |
| FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC FOLFIRI + bevacizumab + QL1706, FOLFIRI + bevacizumab - Colorectal Cancer Metastatic, Microsatellite Stable (MSS) Colorectal Cancer (CRC) | Phase 3 | Not yet recruiting | Sun Yat-sen University | 270 | 2026-07-30 | 2026-07-27 |
| A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Rhabdomyosarcoma | Phase 3 | Recruiting | Children's Oncology Group | 342 | 2026-07-14 | 2026-08-25 |
| A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure BL-M07D1, Oxaliplatin, Calcium levofolinate - Biliary Tract Cancer | Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 398 | 2026-07-07 | 2026-07-24 |
| A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma ZG006, 5-fluorouracil, Calcium folinate and Irinotecan - Neuroendocrine Carcinoma | Phase 3 | Not yet recruiting | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 240 | 2026-07-01 | 2026-05-19 |
| A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01) BL-B01D1, Oxaliplatin, Calcium levofolinate - Biliary Tract Cancer | Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 538 | 2026-06-29 | 2026-07-24 |
| Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) Zoldonrasib, Placebo, Oxaliplatin - Pancreatic Cancer, Pancreatic Cancer Metastatic | Phase 3 | Recruiting | Revolution Medicines, Inc. | 670 | 2026-05-22 | 2026-10-13 |
| A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer Liposomal irinotecan + 5-FU/LV + bevacizumab + Enlonstobart, Irinotecan liposome + 5-FU/LV + Bevacizumab, Irinotecan + 5-FU/LV + Bevacizumab - Metastatic Colorectal Cancer (CRC), Liposomal Irinotecan | Phase 2 / Phase 3 | Not yet recruiting | Hebei Medical University Fourth Hospital | 408 | 2026-05-20 | 2026-05-13 |
| A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment BL-M05D1, Paclitaxel, Docetaxel - Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 3 | Recruiting | Biokin (Shanghai) Biopharmaceutical Co., Ltd. | 438 | 2026-05-15 | 2026-11-02 |
| Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations Biospecimen Collection, Computed Tomography, Fluorouracil - Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 94 | 2026-05-13 | 2026-05-22 |
| A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer Nanvuranlat, Physician's Best Choice - Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC) | Phase 3 | Recruiting | J-Pharma Co., Ltd. | 480 | 2026-05-11 | 2026-09-29 |
| A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma Telisotuzumab adizutecan, Fluorouracil, Folinic acid/ Leucovorina - Metastatic Pancreatic Ductal Adenocarcinoma, PDAC | Phase 2 / Phase 3 | Recruiting | AbbVie | 900 | 2026-04-30 | 2026-10-13 |
| QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma QLC5508, Investigator's Choice of Chemotherapy (docetaxel, paclitaxel, or Irinotecan Hydrochloride) - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 3 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 466 | 2026-04-20 | 2026-04-24 |
| A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients hu1418K322A + Temozolomide + Irinotecan - High-Risk Neuroblastoma | Phase 2 / Phase 3 | Recruiting | Renaissance Pharma Ltd. | 144 | 2026-03-30 | 2026-10-30 |
Showing 20 of 209. Sign in to see all of them.
Colorectal Neoplasms (82) · Colonic Neoplasms (33) · Rectal Neoplasms (32) · Neoplasm Metastasis (16) · Pancreatic Neoplasms (16) · Stomach Neoplasms (15) · Esophageal Squamous Cell Carcinoma (8) · Small Cell Lung Carcinoma (8) · Esophageal Neoplasms (6) · Neoplasms (6) · Gastrointestinal Neoplasms (5) · Digestive System Neoplasms (4) · Intestinal Neoplasms (4) · Rhabdomyosarcoma (4) · Biliary Tract Neoplasms (3)
Alliance for Clinical Trials in Oncology (9) · National Cancer Institute (NCI) (9) · Sun Yat-sen University (9) · Gruppo Oncologico del Nord-Ovest (7) · Pfizer (7) · Children's Oncology Group (6) · Fudan University (5) · Merck Sharp & Dohme LLC (5) · Federation Francophone de Cancerologie Digestive (4) · Jiangsu HengRui Medicine Co., Ltd. (4) · Sanofi (4) · UNICANCER (4) · Sichuan Baili Pharmaceutical Co., Ltd. (3) · Yanhong Deng (3) · Charite University, Berlin, Germany (2)
United States (70) · China (69) · France (44) · Germany (43) · Italy (43) · Canada (32) · Spain (32) · United Kingdom (31) · Belgium (30) · South Korea (28) · Japan (26) · Australia (25) · Netherlands (20) · Taiwan (20) · Puerto Rico (19)
Alfredo Falcone, MD (4) · Alan Venook, MD (2) · Claus-Henning Koehne, MD (2) · Matthew T. Seymour, MA, MD, FRCP (2) · Abha A Gupta (1) · Aimery de Gramont, MD (1) · Al Benson (1) · Alain Piolot, MD (1) · Alexander Stojadinovic, MD (1) · Anders Jakobsen, Prof, MDSc (1)
PMID 41252656, PMID 26861604, PMID 27722750, PMID 30293873, PMID 31268130, PMID 32816630, PMID 35594613, PMID 38603649, PMID 14665611, PMID 15470715, PMID 15677624, PMID 15939923, PMID 16356309, PMID 16648503, PMID 16849748, PMID 17510208, PMID 17553204, PMID 17630037, PMID 17687151, PMID 18065406, PMID 18824706, PMID 19001325, PMID 19073970, PMID 19179549, PMID 19339720, PMID 19349543, PMID 19451425, PMID 19636001, PMID 19690194, PMID 19828593, PMID 19858398, PMID 19884549, PMID 20008640, PMID 20030854, PMID 20052723, PMID 20164695, PMID 20530282, PMID 20697547, PMID 20708966, PMID 20881648, PMID 21422438, PMID 21561347, PMID 21632455, PMID 21742485, PMID 21861888, PMID 21903473, PMID 21997132, PMID 22240792, PMID 22474202, PMID 22949147
2023 (8), U10CA180886 (8), 2015 (4), 2025 (4), U10CA031946 (3), U10CA180821 (3), 2014 (2), 2016 (2), U10CA025224 (2), U10CA032102 (2), U10CA098543 (2), 2017 (1), 2018 (1), 2019 (1), P30CA033572 (1)